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ABSTRACT
Objective: Stability-indicating reversed-phase high-performance liquid chromatography method with photodiode array detection is described for the 
assay of medroxyprogesterone acetate (MDA) and estradiol cypionate (ECA) in bulk and injection dosage form.
Methods: MDA and ECA were determined on a Cosmicsil (250 mm × 4 mm) C18, 5 µm analytical column using mobile phase of 0.1 M KH2PO4 and 
acetonitrile (65:35 v/v) supplied isocratically by a flow rate of 1 ml/min. During stress testing, the sample was subjected to stress with 0.1 N HCl, 0.1 
N NaOH, 30% hydrogen peroxide, water, and 105°C in oven and sunlight. Method validation was done in accordance with international conference on 
harmonization.
Results: The linear response was obtained over the concentration range from 2.5 to 7.5 µg/ml for ECA and 12.5 to 37.50 µg/ml for MDA. The 
recoveries of MDA and ECA were 99.31%–99.45% and 99.59%–99.79%, with relative standard deviation ranging from 0.021% to 0.217% and 0.027% 
to 0.187%, respectively. The limits of detection for MDA and ECA were 0.097 µg/ml and 0.042 µg/ml, respectively. The method was able to selectively 
quantitate MDA and ECA in the presence of the degradation products and, hence, can be considered as stability-indicating one. Proposed method was 
applied to the quantification of MDA and ECA in injection dosage form with good precision and accuracy.
Conclusion: The method can be employed for routine and quality control analysis of MDA and ECA simultaneously.
Keywords: Medroxyprogesterone acetate, Estradiol cypionate, Contraceptive, Quantitation, Stress test.
INTRODUCTION
Medroxyprogesterone acetate (MDA) belongs to a class of drugs called 
progestogens. MDA prevents pregnancy [1]. MDA shows its action by 
preventing the complete development of woman’s egg. MDA through 
thickening the mucus surrounding the cervix makes tough for sperm 
to get to the egg [2]. Furthermore, MDA is used to treat endometriosis, 
uneven or absence of menstrual periods, unusual uterine bleeding, 
reduce the possibility of endometrial hyperplasia (while the person 
is on estrogen therapy), and prevent overgrowth in the lining of 
uterus in postmenopausal women having estrogen replacement 
therapy [3,4]. [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-
trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]
phena nthren-17-yl] acetate is the IUPAC name for MPA and the 
chemical structure is given in Fig. 1.
Estradiol cypionate (ECA) is a prodrug of estradiol, which is a major 
estrogenic steroidal female hormone circulating endogenously in the 
women body [5,6]. ECA shows its effects in the body by binding to the 
estrogen receptor α and β subtypes [7]. These receptors are present in 
ovaries, breasts, skin, prostate, bone, uterus, and brain. For women, ECA 
is prescribed to reduce menopause symptoms such as vaginal dryness 
and hot flashes [8]. ECA is also prescribed to women who cannot 
secrete adequate estrogen due to conditions such as hypogonadism and 
primary ovarian failure. [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-
6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 
3-cyclopentylpropanoate is the IUPAC name for ECA and the chemical 
structure is given in Fig. 1.
In women, MDA and ECA combination is employed as monthly once 
injectable suspension contraceptive to avoid pregnancy [9-12]. When 
given to women, MDA and ECA combination blocks the gonadotropins 
secretion that further stops maturation of follicles and ovulation. This 
combination reduces the sperm penetration by thickening of cervix and 
decreasing the volume of cervical mucus. MDA and ECA combination 
decreases the chances of implantation by thinning of endometrium. To 
the best of our survey on literature, there is only one paper in literature 
on using RP-HPLC as an analytical technique for the determination of 
MDA and ECA [13].
Stress degradation testing plays a significant role in the development of 
a stability-indicating analytical method [14,15]. This testing assists to 
detect and determine the degradation products of drug substance that 
might form at some stage during storage, formulation development, 
manufacturing, and packaging. Therefore, it is recommended to carry out 
stress degradation test to evaluate the effect of acid, alkaline, oxidation, 
temperature, and sunlight on the drug [16]. There is no any analytical 
method reported in literature that analyzes MDA and ECA simultaneously 
using stability-indicating RP-HPLC method. Hence, the purpose of this 
investigation was to develop and validate a stability-indicating RP-HPLC 
method that analyzes MDA and ECA in bulk and injection suspension.
METHODS
Instrumentation
A Waters Alliance HPLC 2695 system with a PDA 2998 detector was 
used for detection and analysis of MDA and ECA. Data acquisition was 
carried out using Empower 2 software.
Materials
Chemicals and solvents used in this investigation are of analytical grade 
(AR) and HPLC grade, respectively. Acetonitrile (HPLC grade) was 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i6.32599
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obtained from Merck India Ltd. (Mumbai, India). Potassium dihydrogen 
phosphate (KH2PO4), hydrogen peroxide (H2O2), hydrochloric acid 
(HCl), and sodium hydroxide (NaOH) used in this study are of AR 
grade and were from SD Fine Chemicals Ltd. (Mumbai, India). MDA 
and ECA standard reference substances were given as gift samples 
by Rainbow Pharma Training Labs (Hyderabad, India). LunelleTM 
injectable suspension with MDA and ECA at 25 mg and 5 mg labeled 
concentration, respectively, was used in this investigation. Water used 
was purified using Millipore purification system (Millipore, USA)
Standard solutions
MDA (250 µg/ml) and ECA (50 µg/ml) stock solution were prepared 
by dissolving appropriate quantities of drugs in the mobile phase. 
Sequential dilutions of stock solution were done with mobile phase to 
reach working standard solutions at five different concentrations for 
calibration curve:
• 2.5, 3.75, 5.0, 6.25, and 7.5 µg/ml of ECA
• 12.5, 18.75, 25, 31.25, and 37.50 µg/ml of MDA.
For testing validation parameters, working standard solution with a 
concentration of 5 µg/ml and 25 µg/ml of ECA and MDA, respectively, 
was prepared from stock solution by dilution with mobile phase.
Optimized chromatographic conditions
Separation and analysis of MDA and ECA were achieved on Cosmicsil 
C18 column (4.6 mm × 250 mm; 5 μm particle size) with an isocratic 
flow rate of 1.0 ml/min. Isocratic mobile phase consisted of 0.1 M 
KH2PO4 and acetonitrile (65:35, v/v), with pH adjusted to 4.0. The 
mobile phase and sample solutions were filtered through 0.45 μm 
membrane filter and degassed earlier to use. Injection volume was 
10 μl for samples and standards. Analyses were performed at 25°C 
temperature. Samples were analyzed with PDA detector at 236 nm.
Calibration curves of MDA and ECA
To establish calibration curve, series of the dilutions of stock solution 
with mobile phase were made to achieve the calibration standards 
of MDA and ECA ranging from 12.5 to 37.50 and 2.5 to 7.5 μg/ml, 
respectively. The solutions are filtered using 0.45 μm membrane filter. 
The solutions were into HPLC system, keeping the injection volume at 
10 μl volume. Calibration curves of MDA and ECA were plotted between 
the drugs peak area and their relevant concentration. Regression 
equation was also derived using the concentration and peak area data.
Assay of MDA and ECA in injection suspension
Powder in the injection bottle, equal to 25 mg of MDA and 5 mg of ECA 
was dissolved in 100 ml of mobile phase in a volumetric flask (100 ml), 
sonicated for 20 min, and filtered through 0.45 μm membrane filter. 
The stock solution was diluted properly with mobile phase to achieve 
a test sample concentration of 5 µg/ml and 25 µg/ml of ECA and 
MDA, respectively. The test sample was analyzed as stated above. The 
amount of MDA and ECA in injection dosage form was computed from 
calibration curves or regression equations of MDA and ECA.
Forced degradation test
A stability-indicating method is one which is defined as a method that 
acceptably enumerates the drug without interference from process 
impurities and degradation products. The stability-indicating ability 
of the proposed RP-HPLC method was assessed by subjecting 10 ml of 
stock injection sample solution (MDA – 250 µg/ml and ECA – 50 µg/ml) 
to accelerated degradation by acid, alkaline, water, thermal, hydrogen 
peroxide, and photolytic conditions. Following degradation, the stock 
injection sample solution was diluted to get test sample (concentration: 
5 µg/ml – ECA and 25 µg/ml – MDA) and analyzed by the proposed 
method. The acidic degradation was performed by preparing the 
sample solution in 0.1 N HCl, sonicated for 30 min at room temperature 
and neutralizing with 0.1 N NaOH. Sample solution prepared in 0.1 N 
NaOH was used for alkaline hydrolysis valuation, where the solution 
was sonicated at room temperature for 30 min and neutralized with 0.1 
N HCl. For the study under neutral situation, the stock injection sample 
is mixed with water and sonicated at room temperature for 30 min. 
Oxidative degradation was induced by mixing the stock injection sample 
solution with 30% H2O2 followed by sonication at room temperature 
for 30 min. Thermal and photodegradation were induced by exposing 
the injection powder in a Petri dish to 105°C for 30 min in oven and 
to sunlight for 24 h, respectively. The degraded samples were injected 
into the HPLC system and analyzed. The stability-indicating ability of 
the proposed method was established by the satisfactory separation of 
degradant peaks from the peaks of MDA and ECA.
RESULTS
Method development
The objective of the current investigation was to develop a stability-
indicating RP-HPLC method for the estimation of MDA and ECA 
simultaneously in bulk and in injection dosage form. Several 
stationary phases (Waters C18, Hibar C18, Inertsil C18, and Cosmicsil 
C18) and mobile phases (orthophosphoric acid:methanol, 0.1 M 
KH2PO4:methanol, and 0.1 M KH2PO4:acetonitrile) with different ratio, 
flow rate, and pH were tested. Finally, a combination of a Cosmicsil 
C18 column (250 mm × 4.6 mm, 5 µm) and a mobile phase of 0.1 M 
KH2PO4:acetonitrile (ratio – 65:35 v/v; flow rate – 1 ml/min; and 
pH 4.0) gave the optimum separation, good peak shape, and sensitivity 
toward MDA and ECA. 236 nm was selected for detection and analysis 
since good sensitivity was found for MDA and ECA at this wavelength. 
A typical chromatogram acquired with the proposed method is 
represented in Fig. 2.
Method validation
As indicated by the International Conference on Harmonization (ICH) 
guidelines Q2 (R1), the developed RP-HPLC method was validated [17].
System suitability test is usually performed to confirm repeatability of 
the chromatographic system, resolution, and column efficiency to make 
sure its capability for the analysis of MDA and ECA. For this test, standard 
drug solution (5 µg/ml – ECA and 25 µg/ml – MDA) was injected into the 
HPLC system 6 times and system suitability parameters were analyzed. 
The values are in limits (Table 1) and confirmed the suitability of the 
method. The column efficiency was >2000 plate count, tailing factors 
are lesser than 2.0, percent relative standard deviation of peak area and 
retention were lesser than 2.0, and resolution is >1.5.
Fig. 1: Structures of drugs selected in this investigation
Fig. 2: Chromatogram of medroxyprogesterone acetate and 
estradiol cypionate after method optimization
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For method selectivity establishment, chromatogram of standard drug 
solution (5 µg/ml – ECA and 25 µg/ml – MDA) was compared with 
chromatograms of placebo blank, blank mobile phase, and injection sample 
solution (5 µg/ml – ECA and 25 µg/ml – MDA) (Fig. 3). The method is 
selective for MDA and ECA analysis because any detectable interfering peaks 
at the retention time of MDA and ECA were not found in chromatograms of 
placebo blank, blank mobile phase, and injection sample solution [18].
The method confirmed linearity in the range of 12.5–37.50 μg/ml 
(MDA) and 2.5–7.5 μg/ml (ECA). The regression line equation was 
y = 75671x + 113.7 for MDA and y = 39586x + 480 for ECA. The goodness 
of fit, regression coefficient (R2), was found to be 0.9996 and 0.9998 for 
MDA and ECA, respectively. The results indicated a linear association 
between the drug concentration and area of peak.
The limit of detection (LOD) and limit of quantitation (LOQ) were 
evaluated on the basis of signal-to-noise ratio (SNR). An SNR of 3:1 
was considered for LOD and 10:1 for LOQ. For this, different dilute 
solutions of MDA and ECA were analyzed by the proposed method. The 
calculated LOD values are 0.042 μg/ml and 0.097 μg/ml for ECA and 
MDA, respectively. While LOQ values are 0.139 μg/ml and 0.324 μg/ml 
for ECA and MDA, respectively. The values proved method sensitivity.
To study proposed method precision, standard drug solution (5 µg/ml 
– ECA and 25 µg/ml – MDA) was injected 6 times and peak area of MDA 
and ECA was recorded. Information shown in Table 2 indicated an 
adequate level of method precision (%RSD value is <2.0%).
Table 1: System suitability values and recommendations
Drug Repeatability of system Column efficiency Resolution and 
percentage 
RSD (n=6)Mean peak area and percentage 
RSD (n=6)









MDA 378,144 and 0.106% 2.478 and 0.046% 3752 and 1.172% 1.256 and 1.207%
ECA 990,436 and 0.183% 4.101 and 0.076% 7126 and 1.264% 1.562 and 0.536% 1.562 and 0.339%
Recommended 
limits
RSD≤2 RSD≤2 >2000 ≤2 ≤1.5
MDA: Medroxyprogesterone acetate, ECA: Estradiol cypionate, RSD: Relative standard deviation
Fig. 3: Chromatograms demonstrating the method selectivity
Table 2: Precision and accuracy for the quantification of 




Peak area* (mAU) RSD (%)
MDA 25 990616 0.017







MDA 25 24.85 99.42
ECA 5 4.98 99.55
*Mean of six values. MDA: Medroxyprogesterone acetate, ECA: Estradiol 
cypionate, RSD: Relative standard deviation
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For studying method accuracy, six standard drug solutions (5 µg/ml 
– ECA and 25 µg/ml – MDA) were analyzed by the proposed method. 
Percent recovery calculated is shown in Table 2. The percent recovery 
value indicates an acceptable level (̴ 100%) of method accuracy.
The blank placebo spiked at three concentrations of MDA and ECA 
was used to evaluate the recovery ability of the method. The recovery 
of MDA and ECA by the proposed method was determined from the 
analysis of three replicate samples at each concentration level. The 
mean recoveries of MDA and ECA are represented in Table 3. No 
significant common excipients effect was observed. Hence, the method 
was selective and accurate.
The method robustness was established by executing the analysis of 
standard drug solution using different detection wavelengths, column 
temperatures, ratio of mobile phase, flow rates, and pH of mobile 
phase [19]. The effect of change on the system suitability parameters 
was studied. In all changed conditions, the system suitability values are 
in limits (Table 4), hence, proved the method robustness.
Stress test was performed, to demonstrate the innate stability of MDA 
and ECA, and to prove specificity and stability-indicating nature of the 
proposed method, as indicated by the ICH guidelines Q1A (R2) [16]. 
After degradation period, the stressed samples were analyzed. The 
presence of related peaks, peak interference, percentage degradation, 
and peak purity for MDA and ECA was checked (Table 5). All the 
conditions assessed in the stress tests resulted in degradation products 
formation (Fig. 4). The stability-indicating ability of the method was 
demonstrated by the adequate separation of degradant peaks from 
MDA and ECA peaks. Peak purity for MDA and ECA peaks was checked 
(peak purity angle < peak threshold) and indicated that they are pure 
from excipients/degradants. As a result, the method is reliable to detect 
any probable change in the drug product analyzes during stability tests.
Application
The proposed method was productively applied to the quantification 
of MDA and ECA simultaneously in injection dosage form. Procedure 
explained in section “Assay of MDA and ECA in injection suspension” 
was followed. Mean percent recovery and percent relative standard 
deviation for MDA and ECA of three determinations were recorded. The 
results are shown in Table 6. The determined content of MDA and ECA 
was equivalent to the respective labeled amounts.
DISCUSSION
The described stability-indicating RP-HPLC technique is sensitive, 
selective, reliable, and reproducible assay method which is successfully 
applied to separate and analyze MDA and ECA in the presence of their 
degradation products, to determine MDA and ECA content in injection 
dosage form. The use of photodiode array detector was a supportive 
tool for peak identity and purity of MDA and ECA under different 
conditions of degradation. The parameters of system suitability are 
within the acceptability limits. The linearity curve acquired shows a 
close relationship between concentration of drugs (MDA and ECA) and 
peak areas (MDA and ECA). The method was accurate, as the percentage 
of recovery was close to 100%. The RSD values below 1% signify the 
method’s precision. The method has been demonstrated as specific 
since there is no interference in placebo peak and blank mobile phase 
Table 3: Recovery of medroxyprogesterone acetate and estradiol cypionate using proposed method
Drug Concentration added Concentration found* (µg/ml) Recovery* (%) RSD (%)
MDA 12.5 12.430 99.45 0.067
25.0 24.857 99.43 0.021
37.50 37.243 99.31 0.217
ECA 2.5 2.497 99.79 0.186
5.0 4.977 99.60 0.110
7.5 7.470 99.59 0.027
*Mean of three values. MDA: Medroxyprogesterone acetate, ECA: Estradiol cypionate, RSD: Relative standard deviation
Table 4: Effect of slight changes on the system suitability data of medroxyprogesterone acetate and estradiol cypionate
HPLC condition Value MDA ECA
Theoretical plates Tailing Resolution Theoretical plates Tailing
Flow rate (ml/min) 0.9 6925 1.57 8.45 3524 1.25
1.1 7608 1.58 8.67 3722 1.26
Column temperature (°C) 23 8064 1.57 8.79 3808 1.22
27 8142 1.58 9.01 3937 1.22
Mobile phase ratio (0.1 M KH2 PO4:acetonitrile) 60:40 7608 1.58 8.67 3722 1.26
70:30 8064 1.57 8.79 3808 1.22
Mobile phase pH 3.9 7121 1.57 8.68 3546 1.24
4.1 7287 1.56 8.76 3661 1.24
Detection wavelength (nm) 234 7062 1.55 8.71 3570 1.29
238 7130 1.56 8.70 3590 1.23
MDA: Medroxyprogesterone acetate, ECA: Estradiol cypionate, HPLC: High-performance liquid chromatography
Table 5: Results of medroxyprogesterone acetate and estradiol cypionate stress test
Stress applied MDA ECA Rt of Deg
%Deg PPA PT %Deg PPA PT
0.1 N HCl 13.37 0.389 0.589 12.41 0.271 0.754 3.267, 3.785
0.1 N NaOH 10.07 0.286 0.487 10.77 0.295 0.652 3.688
30% H2O2 10.81 0.190 0.486 9.72 0.358 0.657 1.587, 3.777
105°C 13.34 0.209 0.584 12.76 0.464 0.853 3.254, 3.610, 5.747
Sunlight 11.61 0.241 0.586 11.54 0.357 0.862 0.162, 3.265, 3.615, 7.180, 7.594
H2O 7.9 0.381 0.584 8.77 0.214 0.756 3.279, 3.756
%Deg: Percentage degradation, PPA: Peak purity angle, PT: Purity threshold, Rt of Deg: Retention of degradants
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as to the retention time of MDA and ECA. Forced degradation studies 
indicated stability-indicating ability of the method proposed.
CONCLUSION
The stability-indicating RP-HPLC method for the simultaneous analysis 
of MDA and ECA is described using Cosmicsil (250 mm × 4 mm) 
C18, 5 µm analytical column, and mobile phase of 0.1 M KH2PO4 and 
acetonitrile (65:35 v/v). The method has been found to be reliable 
and suitable for the assay of MDA and ECA in the presence of stress 
degradants. This method was simple, sensitive, rapid, accurate, precise, 
and free from interference by excipients and degradants. Due to these 
features, this method can be employed for routine and quality control 
analysis.
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